Genzyme/BioMarin Aldurazyme
Executive Summary
FDA's Endocrinologic & Metabolic Drugs Advisory Committee will consider Genzyme/BioMarin's Aldurazyme (laronidase) for treatment of mucopolysaccharidosis 1 on Jan. 15. A rolling BLA submission for the enzyme replacement therapy was initiated April 12; FDA has granted Aldurazyme orphan drug designation and fast-track status. The meeting begins at 8 a.m. at the Holiday Inn in Bethesda, Md. [To view a 1webcast/video of this meeting, go to FDAAdvisoryCommittee.com]...
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.